New Delhi, April 14
Surging ahead with an impressive growth in sales of its products, the Indian Medicines Pharmaceutical Corporation Limited (IMPCL), the public sector manufacturing unit of the Ministry of AYUSH, has recorded a turnover of Rs 164.33 crore for the financial year 2020-21.
The ministry termed the growth as a reflection of the fast-growing adoption of AYUSH products and services by the public in the wake of the Covid-19 pandemic.
According to the statement, the World Health Organization (WHO) had recently recommended 18 Ayurvedic products of IMPCl for WHO-GMP/COPP certification subject to certain observations.
"to companies after conducting an inspection. This certification is an endorsement of the quality of IMPCL's products. It will help IMPCL commence export operation of quality medicines at a global level."
The 'World Health Organization, Good Manufacturing Practices/Certificate of Pharmaceutical Product (WHO-GMP/CoPP)' certification is given to companies after conducting an inspection. This certification is an endorsement of the quality of IMPCL's products that will help it to commence export operations of quality medicines at a global level.
Every government institution doing business with IMPCL has praised the company for providing steady support to various health programmes and ensuring an unbroken supply of products during the Covid-19 pandemic, the ministry said.
Presently, the IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for various diseases, it said.
Disclaimer: This story was supplied by an external content provider; we do not endorse or accept responsibility for its accuracy, completeness, or any outcomes from relying on it. It is for informational purposes only and does not constitute legal, financial, medical, or other professional advice. Laws and regulations vary and may change; readers should verify accuracy and compliance with local requirements and consult a qualified professional for tailored guidance.